Teresa Cesena

The medical writing and transparency teams have grown significantly under her leadership, and one of her key responsibilities has been to ensure that onboarding, training, and mentoring continue to maintain high levels of quality. Teresa oversees initiatives that enable the team to stay ahead of industry trends and regulations and is responsible for overseeing teams who can execute deliverables in a variety of models, including in FSP partnerships. In addition, she manages teams with expertise in related technologies and tech-enabled solutions, like Automatiqc® quality tool.

She holds a Ph.D. in Cellular and Molecular Biology from the University of Michigan and is an instructor for MMS Academy.

Suggested For You

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

webinar

March 26th, 2026

Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 30th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development